<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26882" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pemphigus Foliaceus</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lepe</surname>
            <given-names>Kenia</given-names>
          </name>
          <aff>Universidad de Guadalajara</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yarrarapu</surname>
            <given-names>Siva Naga S.</given-names>
          </name>
          <aff>Monmouth Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kenia Lepe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Siva Naga Yarrarapu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26882.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pemphigus is a potentially life-threatening, autoimmune blistering disease characterized by the presence of circulating antibodies against desmogleins, key components of epidermal intercellular adhesion. In contrast to pemphigus vulgaris, in which mucosal lesions are classically present, pemphigus foliaceus does not involve mucosal lesions and only involves skin involvement. Pemphigus foliaceus involves immunoglobulin G (IgG) antibodies directed against desmoglein-1 (Dsg1) found in the granular layer of the epidermis. This activity describes the evaluation and management of pemphigus foliaceus and highlights the role of the interprofessional team in improving care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the pathophysiology of pemphigus foliaceus.</p></list-item><list-item><p>Describe the typical presentation of pemphigus foliaceus.</p></list-item><list-item><p>Outline the treatment options for pemphigus foliaceus.</p></list-item><list-item><p>Explain the importance of improving care coordination amongst interprofessional team members to optimize outcomes for patients affected by pemphigus foliaceus.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26882&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26882">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26882.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pemphigus is a potentially life-threatening, autoimmune blistering disease characterized by the presence of circulating antibodies against desmogleins, key components of the integrity of epidermal intercellular adhesion. However, in contrast to pemphigus vulgaris (PV) where mucosal lesions are classically present,&#x000a0;pemphigus foliaceus (PF) there is only skin involvement without mucosal lesions. &#x000a0;As an acquired form of pemphigus, pemphigus foliaceus is caused by&#x000a0;immunoglobulin G (IgG) antibodies directed against desmoglein-1 (Dsg1) found in the granular layer of the epidermis.<xref ref-type="bibr" rid="article-26882.r1">[1]</xref><xref ref-type="bibr" rid="article-26882.r2">[2]</xref></p>
      </sec>
      <sec id="article-26882.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Susceptibility to pemphigus foliaceus has been correlated with the presence of HLA-DR4, DR-14, and DR-1, but unlike pemphigus vulgaris, no single allele has been associated with the disease.<xref ref-type="bibr" rid="article-26882.r3">[3]</xref><xref ref-type="bibr" rid="article-26882.r4">[4]</xref></p>
      </sec>
      <sec id="article-26882.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Pemphigus foliaceous is less common worldwide than pemphigus vulgaris. Pemphigus foliaceous affects men and women equally, and the mean age of onset is usually 50 to 60 years. However, PF has been reported in children.</p>
        <p>Endemic pemphigus foliaceus is common in Tunisia and Brazil, where it is also commonly known as fogo selvagem. This endemic form frequently occurs in genetically related family members, although it is not contagious, and to date, spread by blood products or body fluids has not been documented.&#x000a0;<xref ref-type="bibr" rid="article-26882.r5">[5]</xref><xref ref-type="bibr" rid="article-26882.r6">[6]</xref></p>
      </sec>
      <sec id="article-26882.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Experimental evidence suggests that autoantibodies in all forms of pemphigus foliaceus are pathogenic. Those autoantibodies recognize desmoglein-1 (Dsg1), a 160-KDa desmosomal cadherin, which is expressed more strongly in the skin from the upper torso. Dsg1 is present but only weakly in mucosae, accounting for the lack of mucosal involvement in pemphigus foliaceous. Some patients have also desmoglein-3 antibodies in the absence of clinical evolution.<xref ref-type="bibr" rid="article-26882.r7">[7]</xref></p>
        <p>Patients with both sporadic and endemic forms of pemphigus foliaceus have antibodies anti- Dsg1, the titer correlating both with the extent and activity of the disease.<xref ref-type="bibr" rid="article-26882.r8">[8]</xref></p>
        <p>Some cases have been associated with the use of certain drugs. In patients receiving penicillamine, pemphigus foliaceus is seen more commonly than pemphigus vulgaris, with a ratio of 4:1. Penicillamine and captopril contain sulfhydryl groups that are speculated to interact with the sulfhydryl groups in Dsg1 and Dsg3. Most patients with drug-induced pemphigus go into remission after the offending drug is discontinued.<xref ref-type="bibr" rid="article-26882.r9">[9]</xref></p>
      </sec>
      <sec id="article-26882.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histopathology of early blisters in pemphigus foliaceus demonstrates acantholysis just below de stratum corneum and in the granular layer. The stratum corneum is often lost from the surface. The deeper epidermis remains intact. Histological features may not be diagnostic in the early stages, and eosinophilic spongiosis is an early manifestation.</p>
        <p>In early lesions, vacuoles form in the intercellular spaces in the upper levels of the epidermis. These coalesce to form clefts and superficial bullae high in the granular layer or immediately below the stratum corneum. Bullae contain fibrin, neutrophils, and scattered acantholytic keratinocytes. These superficial blisters are histologically indistinguishable from those seen in staphylococcal scalded skin syndrome or bullous impetigo because Dsg1 is targeted in both of these diseases.</p>
        <p>Older lesions are acanthotic, papillomatous, and hyperkeratotic with focal parakeratosis. Dyskeratotic cells in the granular layer of older lesions distinguish pemphigus foliaceus from pemphigus vulgaris. The dermis may show an inflammatory infiltrate of eosinophils and neutrophils.<xref ref-type="bibr" rid="article-26882.r1">[1]</xref><xref ref-type="bibr" rid="article-26882.r10">[10]</xref></p>
      </sec>
      <sec id="article-26882.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>It should be noted that most patients with PF are not severely ill. Patients may complain of burning, pruritis, and pain.&#x000a0;The onset is usually subtle with a few scattered, crusted lesions involving the seborrheic areas: scalp, face, chest, and upper back. Blisters are typically not found or clinically evident because they are superficial and rupture easily, often only the resultant crust and scale are seen. The Nikolsky sign is present. The disease may stay localized for years, or it may rapidly progress to generalized involvement, resulting in exfoliative erythroderma. Mucous membrane involvement is uncommon, even with widespread disease.</p>
        <p>Variants of pemphigus foliaceus have been described, including pemphigus resembling dermatitis herpetiformis, especially in its early phase (pemphigus herpetiformis). Widespread clusters of pruritic papules and vesicles develop on an erythematous background. The condition usually evolves into classical pemphigus foliaceus but has also been described as preceding pemphigus vulgaris. In general, the clinical course is benign.</p>
        <p>Pemphigus erythematosus (Senear-Usher syndrome) is a variant, in which patients have immunological features of both lupus erythematosus and pemphigus: IgG and C3 deposition at the basement membrane zone and on the cell surfaces of keratinocytes, in addition to circulating antinuclear antibodies. Progression to lupus erythematosus is rare. Clinically it manifests as scaly, erythematous lesions over the nose and malar region of the face, in a butterfly distribution. Sunlight may exacerbate the disease. Oral mucosa is rarely involved.</p>
        <p>Myasthenia gravis, thymoma, or both have been associated with pemphigus vulgaris and pemphigus foliaceus.<xref ref-type="bibr" rid="article-26882.r11">[11]</xref></p>
      </sec>
      <sec id="article-26882.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A complete review of medications should be done to exclude the possibility of drug-induced pemphigus foliaceus.</p>
        <p>Diagnosis of pemphigus relies on skin biopsy of a fresh lesion for histology to determine the site of blister formation, a well as a confirmatory immunochemical study to document the presence of skin autoantibodies, either by direct immunofluorescence of perilesional skin or direct immunofluorescence (DIF) of ELISA.</p>
        <p>The hallmark of pemphigus is the finding of IgG autoantibodies against the cell surface of keratinocytes with DIF. The diagnosis of pemphigus should be seriously questioned if the test result of direct immunofluorescence is negative. It is important that the biopsy for direct immunofluorescence be performed on the normal-appearing perilesional skin, as immune reactants can be difficult to detect in the blistered epidermis</p>
        <p>Direct and indirect immunofluorescent findings are usually indistinguishable from pemphigus vulgaris, with intercellular IgG and C3 throughout the epidermis. Occasionally intercellular staining is restricted to the upper layers of the epidermis, both on direct and indirect immunofluorescence.</p>
        <p>Indirect immunofluorescence is positive in over 85% of pemphigus foliaceus, ELISA detects anti-desmoglein-1 antibodies in up to 71% of patients, but immunoblotting is less sensitive.<xref ref-type="bibr" rid="article-26882.r12">[12]</xref></p>
        <p>Recently, trichoscopy has been evaluated as a useful tool in the differential diagnosis of scalp pemphigus. Extravasations and yellow hemorrhagic crusts were the most frequent findings. The &#x0201c;fried egg sign&#x0201d; (yellow dots with a whitish halo) was identified as a new trichoscopic feature of pemphigus.<xref ref-type="bibr" rid="article-26882.r13">[13]</xref><xref ref-type="bibr" rid="article-26882.r1">[1]</xref></p>
      </sec>
      <sec id="article-26882.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Before the advent of steroid therapy, pemphigus foliaceus was fatal in approximately 60% of patients, and almost always fatal in elderly patients with concurrent medical problems. With steroid and immunosuppressive therapy, the mortality has been dramatically reduced.</p>
        <p>Corticosteroids represent the first-line treatment in all forms of pemphigus. Prednisone at 0.5 to 1.5 mg/kg per day or prednisolone 20 to 40 mg per day may be used. If initial control is not reached within 2 weeks, a higher prednisone dose is advised.</p>
        <p>Azathioprine 1 to 3 mg/kg per day and mycophenolate mofetil 2 g per day are effective adjuvants to oral steroids but the best time for its introduction remains unclear (early versus treatment-resistant cases). It should be noted that the onset of action with mycophenolate mofetil is slow and evidence of response occurs between 2 and 12 months of continued use.</p>
        <p>Other treatment options for refractory disease, or in case of contraindications to immunosuppressive agents include hydroxychloroquine 200 mg twice daily, dapsone 100 mg per day or up to 1.5 mg/kg per day, methotrexate 10 to 20 mg/week, intravenous immunoglobulin 2 g/kg per month or rituximab, given as either 4 weekly infusions of 375 mg/m2 or as 2 1-g infusions, separated by 2 weeks.</p>
        <p>Due to the potential side effects of therapy, patients should be monitored closely. After discontinuation of systemic corticosteroids in patients with complete remission, adjuvant immunosuppression can also be reduced over 6 to 12 months. The discontinuation of therapy is based on the clinical presentation with a complete absence of active cutaneous lesions over several months. Negative or low ELISA-Dsg1 values or negative immunofluorescence are useful to support the discontinuation of therapy.<xref ref-type="bibr" rid="article-26882.r1">[1]</xref><xref ref-type="bibr" rid="article-26882.r14">[14]</xref><xref ref-type="bibr" rid="article-26882.r15">[15]</xref></p>
      </sec>
      <sec id="article-26882.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis includes other forms of pemphigus, bullous impetigo, subcorneal pustular dermatosis, subacute cutaneous lupus erythematosus, and seborrheic dermatitis. The demonstration of IgG autoantibodies against epidermal surfaces is essential to determine if the disorder accounts for a form of pemphigus.</p>
      </sec>
      <sec id="article-26882.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Pemphigus foliaceus is regarded as a benign disease that&#x000a0;responds well to treatment and may remit. Pemphigus erythematosus may persist as a localized disease for years. The clinical course is often similar to pemphigus foliaceous.</p>
      </sec>
      <sec id="article-26882.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pemphigus foliaceus is best managed by an interprofessional team including pharmacists. Patients respond to corticosteroids but some may require more potent immunosuppressives. The pharmacist should educate the patient about compliance and potential adverse effects. For those who remain compliant, the outlook is good. Without treatment, the condition can lead to poor quality of life.</p>
      </sec>
      <sec id="article-26882.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26882&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26882">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/pemphigus-foliaceus/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26882">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26882/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26882">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26882.s14">
        <title>References</title>
        <ref id="article-26882.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murrell</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Pe&#x000f1;a</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marinovic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Daneshpazhooh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eming</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jonkman</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Mimouni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Borradori</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Yamagami</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lehman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Saleh</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Culton</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Czernik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zone</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fivenson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ujiie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wozniak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akman-Karaka&#x0015f;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korman</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Caux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Drenovska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Prost-Squarcioni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vassileva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Cardones</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ioannides</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jedlickova</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Palisson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Patsatsi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uzun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yayli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amagai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hertl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Grando</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cianchini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Feliciani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iranzo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mascar&#x000f3;</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kowalewski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Groves</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harman</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Marinkovich</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Maverakis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Werth</surname>
                <given-names>VP</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of pemphigus: Recommendations of an international panel of experts.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>82</volume>
            <issue>3</issue>
            <fpage>575</fpage>
            <page-range>575-585.e1</page-range>
            <pub-id pub-id-type="pmid">29438767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioannides</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hytiroglou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Phelps</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Bystryn</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus, and pemphigus vulgaris antigens in human skin.</article-title>
            <source>J Invest Dermatol</source>
            <year>1991</year>
            <month>Feb</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-61</page-range>
            <pub-id pub-id-type="pmid">1991976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warren</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Arteaga</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Rivitti</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hans-Filho</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Qaqish</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Giudice</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus.</article-title>
            <source>J Invest Dermatol</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>104</fpage>
            <page-range>104-8</page-range>
            <pub-id pub-id-type="pmid">12535205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arteaga</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Prisayanh</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MS</given-names>
              </name>
              <collab>Cooperative Group on Fogo Selvagem Research</collab>
            </person-group>
            <article-title>A subset of pemphigus foliaceus patients exhibits pathogenic autoantibodies against both desmoglein-1 and desmoglein-3.</article-title>
            <source>J Invest Dermatol</source>
            <year>2002</year>
            <month>May</month>
            <volume>118</volume>
            <issue>5</issue>
            <fpage>806</fpage>
            <page-range>806-11</page-range>
            <pub-id pub-id-type="pmid">11982757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pollmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eming</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hertl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-25</page-range>
            <pub-id pub-id-type="pmid">29313220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santi</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Sotto</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Immunopathologic characterization of the tissue response in endemic pemphigus foliaceus (fogo selvagem).</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>446</fpage>
            <page-range>446-50</page-range>
            <pub-id pub-id-type="pmid">11209113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokol</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>GFH</given-names>
              </name>
              <name>
                <surname>Kuipers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jonkman</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Pas</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Giepmans</surname>
                <given-names>BNG</given-names>
              </name>
            </person-group>
            <article-title>Large-Scale Electron Microscopy Maps of Patient Skin and Mucosa Provide Insight into Pathogenesis of Blistering Diseases.</article-title>
            <source>J Invest Dermatol</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>135</volume>
            <issue>7</issue>
            <fpage>1763</fpage>
            <page-range>1763-1770</page-range>
            <pub-id pub-id-type="pmid">25789704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kawada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amagai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Pemphigus erythematosus: detection of anti-desmoglein-1 antibodies by ELISA.</article-title>
            <source>Dermatology</source>
            <year>1999</year>
            <volume>199</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-9</page-range>
            <pub-id pub-id-type="pmid">10559598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shirakata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Amagai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hanakawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1.</article-title>
            <source>J Invest Dermatol</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-8</page-range>
            <pub-id pub-id-type="pmid">9424092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jordan</surname>
                <given-names>TJM</given-names>
              </name>
              <name>
                <surname>Affolter</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Outerbridge</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Goodale</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological findings and clinical outcomes in 49 cases of feline pemphigus foliaceus examined in Northern California, USA (1987-2017).</article-title>
            <source>Vet Dermatol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-e65</page-range>
            <pub-id pub-id-type="pmid">30779233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sawamura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kajihara</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Makino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Makino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jinnin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oyama</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ihn</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Systemic lupus erythematosus associated with myasthenia gravis, pemphigus foliaceus and chronic thyroiditis after thymectomy.</article-title>
            <source>Australas J Dermatol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>e120</fpage>
            <page-range>e120-e122</page-range>
            <pub-id pub-id-type="pmid">27270472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bystryn</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>2 Pt 1</issue>
            <fpage>211</fpage>
            <page-range>211-6</page-range>
            <pub-id pub-id-type="pmid">9270506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sar-Pomian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurzeja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rudnicka</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Olszewska</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The value of trichoscopy in the differential diagnosis of scalp lesions in pemphigus vulgaris and pemphigus foliaceus.</article-title>
            <source>An Bras Dermatol</source>
            <year>2014</year>
            <season>Nov-Dec</season>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>1007</fpage>
            <page-range>1007-12</page-range>
            <pub-id pub-id-type="pmid">25387515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.</article-title>
            <source>Eur J Dermatol</source>
            <year>2002</year>
            <season>Mar-Apr</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>174</fpage>
            <page-range>174-8</page-range>
            <pub-id pub-id-type="pmid">11872417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26882.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hymes</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Jordon</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Pemphigus foliaceus. Use of antimalarial agents as adjuvant therapy.</article-title>
            <source>Arch Dermatol</source>
            <year>1992</year>
            <month>Nov</month>
            <volume>128</volume>
            <issue>11</issue>
            <fpage>1462</fpage>
            <page-range>1462-4</page-range>
            <pub-id pub-id-type="pmid">1444499</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
